+

WO2008148490A8 - Hsp27 as biomarker for alzheimer's disease - Google Patents

Hsp27 as biomarker for alzheimer's disease Download PDF

Info

Publication number
WO2008148490A8
WO2008148490A8 PCT/EP2008/004235 EP2008004235W WO2008148490A8 WO 2008148490 A8 WO2008148490 A8 WO 2008148490A8 EP 2008004235 W EP2008004235 W EP 2008004235W WO 2008148490 A8 WO2008148490 A8 WO 2008148490A8
Authority
WO
WIPO (PCT)
Prior art keywords
hsp27
disease
alzheimer
level
variant
Prior art date
Application number
PCT/EP2008/004235
Other languages
French (fr)
Other versions
WO2008148490A1 (en
Inventor
Peter Berndt
Bernd Bohrmann
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of WO2008148490A1 publication Critical patent/WO2008148490A1/en
Publication of WO2008148490A8 publication Critical patent/WO2008148490A8/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to a method for assessing Alzheimer's disease in vitro comprising measuring the level of HSP27, or a variant thereof in a sample collected from an individual, wherein an altered level of said protein, or a variant thereof, is indicative that said individual suffers from Alzheimer's disease. Furthermore, the present invention relates to a method for monitoring the progression of the Alzheimer's disease in vitro comprising measuring the level of HSP27, or a variant thereof in a sample collected from an individual, wherein an altered level of HSP27 compared with an earlier measurement of the level of HSP27, or a variant thereof, is indicative for the progression of Alzheimer's disease of said individual.
PCT/EP2008/004235 2007-06-04 2008-05-28 Hsp27 as biomarker for alzheimer's disease WO2008148490A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07109516 2007-06-04
EP07109516.0 2007-06-04

Publications (2)

Publication Number Publication Date
WO2008148490A1 WO2008148490A1 (en) 2008-12-11
WO2008148490A8 true WO2008148490A8 (en) 2009-11-19

Family

ID=39681049

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/004235 WO2008148490A1 (en) 2007-06-04 2008-05-28 Hsp27 as biomarker for alzheimer's disease

Country Status (1)

Country Link
WO (1) WO2008148490A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017521092A (en) * 2014-05-16 2017-08-03 ヴィトルヴィアン バイオメディカル， インク．Ｖｉｔｒｕｖｉａｎ Ｂｉｏｍｅｄｉｃａｌ， Ｉｎｃ． Diagnostic testing and treatment / prevention of Alzheimer's disease

Also Published As

Publication number Publication date
WO2008148490A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
EP3355059A3 (en) Biomarker assay of neurological condition
WO2006113245A3 (en) Methods for measuring glycan levels of proteins
WO2010053587A3 (en) Methods of monitoring conditions by sequence analysis
CY1110116T1 (en) Neuroendocrine indicators for depression
WO2008148072A3 (en) Disease-associated genetic variations and methods for obtaining and using same
HK1115636A1 (en) Use of cyfra 21-1 as a marker for colorectal cancer cyfra 21-1
ATE554389T1 (en) APEX AS A MARKER FOR LUNG CANCER
IN2014MN02060A (en)
EP2448485A4 (en) ANALYTE SENSOR
EP2387711A4 (en) METHODS FOR DETERMINING PATIENT RESPONSE BY MEASURING HER-3
WO2014066913A8 (en) Health diagnostic systems and methods
WO2008089994A8 (en) Use of igfbp-7 in the assessment of heart failure
WO2007090126A3 (en) Compositions and methods for detecting and quantifying toxic substances in disease states
EP3156925A3 (en) Copd biomarker signatures
WO2010061283A8 (en) Biomarkers for diagnosing and detecting the progression of neurodegenerative disorders, in particular of amyotrophic lateral sclerosis
PL2021794T3 (en) Use of protein s100a 12 as a marker for colorectal cancer
AU2010202926B2 (en) Markers and methods relating to the assessment of Alzheimer's disease
WO2011022436A3 (en) Computer-automated spatial analysis
EP2889591A3 (en) Method of Determining Vehicle Scale Health and Suitability for Use via Weight Transfer Pattern Analysis
EP2579043A4 (en) DETECTION METHOD
WO2011005893A3 (en) Biomarkers and methods for detecting alzheimer's disease
WO2010136163A8 (en) Secernin-1 as a marker for cancer
EP2557421A3 (en) Altered mitochondrial activity in diseases resulting from oxidative stress
WO2012032345A3 (en) Biomarker signatures and uses thereof
WO2011109112A3 (en) Method of detecting tau protein and tau fragments in serum

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08758819

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08758819

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载